Weight Management with GLP-1

Medically supervised weight management using GLP-1 Semaglutide injections (Ozempic/Wegovy) combined with dietary guidance and monitoring by aesthetic medicine doctors.

The Aesthetic Studio offers medically supervised weight management using GLP-1 (glucagon-like peptide-1) receptor agonists, specifically Semaglutide — the active ingredient in Ozempic and Wegovy — as part of a structured clinical weight loss programme. GLP-1 receptor agonists represent a significant advance in medical weight management, having demonstrated clinically meaningful weight loss of 10–15% of body weight in randomised controlled trials when combined with lifestyle modifications. Semaglutide works by mimicking the body's natural GLP-1 hormone, which is released after eating. It signals the hypothalamus to reduce appetite and increase feelings of fullness (satiety), slows gastric emptying to prolong the sensation of being full after meals, and reduces cravings — particularly for high-calorie foods. The net effect is a significant reduction in caloric intake without the willpower struggle associated with conventional dieting. At The Aesthetic Studio, the GLP-1 programme is delivered under the supervision of licensed aesthetic medicine physicians who assess patient suitability (including contraindications such as personal or family history of thyroid cancer), prescribe appropriate starting and escalation doses, monitor for side effects such as nausea and vomiting (which are common early in treatment and managed through dose titration), and provide regular check-ins throughout the programme. The injectable medication is administered once weekly by the patient at home using a pre-filled pen injector, with clinic follow-ups scheduled monthly or as needed. The programme is typically combined with dietary advice and, where indicated, body contouring treatments to address residual fat deposits or skin laxity after weight loss.